AMAG Pharmaceuticals (NASDAQ:AMAG) Downgraded by ValuEngine to Buy

AMAG Pharmaceuticals (NASDAQ:AMAG) was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, ValuEngine reports.

Other equities research analysts have also issued research reports about the stock. BidaskClub raised shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Friday, October 25th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of AMAG Pharmaceuticals in a research note on Thursday, August 8th. Barclays reaffirmed a “buy” rating and set a $14.00 target price (down previously from $16.00) on shares of AMAG Pharmaceuticals in a research note on Sunday, November 3rd. Finally, Piper Jaffray Companies cut shares of AMAG Pharmaceuticals from a “neutral” rating to an “underweight” rating and lowered their target price for the stock from $9.00 to $6.00 in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $13.28.

NASDAQ AMAG opened at $10.87 on Tuesday. AMAG Pharmaceuticals has a one year low of $6.81 and a one year high of $19.44. The company has a market capitalization of $368.60 million, a price-to-earnings ratio of -2.80 and a beta of 0.35. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.53 and a current ratio of 1.67. The company’s 50-day simple moving average is $10.56 and its two-hundred day simple moving average is $10.35.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Friday, November 1st. The specialty pharmaceutical company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.19). AMAG Pharmaceuticals had a negative return on equity of 34.59% and a negative net margin of 88.54%. The company had revenue of $84.13 million during the quarter, compared to analyst estimates of $88.25 million. During the same quarter last year, the business earned $0.89 earnings per share. The firm’s revenue for the quarter was down 31.2% on a year-over-year basis. Equities analysts expect that AMAG Pharmaceuticals will post -2.48 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of Montreal Can boosted its position in shares of AMAG Pharmaceuticals by 211.9% during the 2nd quarter. Bank of Montreal Can now owns 3,209 shares of the specialty pharmaceutical company’s stock valued at $32,000 after acquiring an additional 2,180 shares during the last quarter. Tyers Asset Management LLC boosted its position in shares of AMAG Pharmaceuticals by 32.2% during the 2nd quarter. Tyers Asset Management LLC now owns 5,840 shares of the specialty pharmaceutical company’s stock valued at $58,000 after acquiring an additional 1,424 shares during the last quarter. Riverhead Capital Management LLC boosted its position in shares of AMAG Pharmaceuticals by 30.1% during the 2nd quarter. Riverhead Capital Management LLC now owns 6,483 shares of the specialty pharmaceutical company’s stock valued at $65,000 after acquiring an additional 1,500 shares during the last quarter. Aperio Group LLC acquired a new position in shares of AMAG Pharmaceuticals during the 2nd quarter valued at about $78,000. Finally, Elkfork Partners LLC boosted its position in shares of AMAG Pharmaceuticals by 32.2% during the 2nd quarter. Elkfork Partners LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $80,000 after acquiring an additional 1,958 shares during the last quarter.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Featured Story: Trading Ex-Dividend

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.